Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
resource-stratified-guidelines. Copyright © 2021 by American Society of Clinical Oncolog y.
All rights reserved.
Abbreviations
BRCA, BReast CAncer gene; CA-125, cancer antigen 125; CEA, carcinoembryonic
antigen; CT, computed tomography; FIGO, International Federation of Gynecolog y
and Obstetrics; FSA, functional status assessment; IP, intraperitoneal chemotherapy;
LMP, low malignant potential; MRI, magnetic resonance imaging ; NACT, neoadjuvant
chemotherapy; OS, overall survival; PARPi, poly (ADP-ribose) polymerase inhibitor; PS,
performance status; TVU, transvaginal ultrasound
Source
Vanderpuye VD, Clemenceau JRV, Temin S, et al. Assessment of Adult Women With
Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified
Guideline. JCO Glob Oncol. 2021 Jun 29;7:1032-1066. doi: 10.1200/GO.21.00085.
PMID: 34185571.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2021 All rights reserved
ASCOOV08213a
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/resource-stratified-guidelines.
